CSWYY'
s EV-to-FCF Range Over the Past 10 Years
Min: -2.45 Med: 1.03 Max: 21.42
Current: -2.45
During the past 13 years, the highest EV-to-FCF of China Shineway Pharmaceutical Group was 21.42. The lowest was -2.45. And the median was 1.03.
CSWYY's EV-to-FCF is ranked better than 99.11% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.16
vs CSWYY: -2.45
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China Shineway Pharmaceutical Group (OTCPK:CSWYY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China Shineway Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:
China Shineway Pharmaceutical Group's share price for today is $19.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Shineway Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $3.534.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
China Shineway Pharmaceutical Group EV-to-FCF Related Terms
China Shineway Pharmaceutical Group EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group EV-to-FCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's EV-to-FCF falls into.
China Shineway Pharmaceutical Group's current Enterprise Value is $-292.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Shineway Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $137.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group (CSWYY) has a EV-to-FCF of -2.13 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on China Shineway Pharmaceutical Group and its competitors. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #5 out of 562 companies in the Drug Manufacturers industry, placing it in the top 0.90000000000001%.
Is China Shineway Pharmaceutical Group's EV-to-FCF too high?
China Shineway Pharmaceutical Group's current EV-to-FCF is -2.13. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #5 out of 562 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #5 out of 562 companies for EV-to-FCF. This places China Shineway Pharmaceutical Group in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.16, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current EV-to-FCF is -2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current EV-to-FCF of -2.13. The stock's GF Value™ is $16.85, compared to a current price of $19.25 — trading 14.2% above its estimated fair value. The current EV-to-FCF is -2.13. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current EV-to-FCF is -2.13 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 14.2% above its estimated GF Value™ of $16.85.
Key valuation signals for CSWYY:
EV-to-FCF: -2.13
GF Value™: $16.85 vs. price of $19.25 (14.2% above fair value)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score
Get the complete analysis for CSWYY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
